Petra Acquisition, Inc. (NASDAQ:PAIC), in a press release today regarding it’s Phase 2b trials for REVTx-99, also announced that its shareholders approved its combination with biotech firm Revelation Biosciences in a meeting held last week.
Unfortunately, nothing has been filed yet and Petra did not disclose much information regarding the deal, including redemption figures. However, the combined company is expected to begin trading today on the Nasdaq under “REVB” and “REVBW”.
The SPAC recently added forward purchase agreements and a convertible note that added up to $12 million to its combination with Revelation. Of this amount, $4.5 million is to be used to backstop potential redemptions with financing from AXA Prime Impact Master Fund, LifeSci Venture Partners as well as other Petra and Revelation institutional investors. Meteora Capital and affiliates have also agreed to purchase 750,000 shares from redeeming shareholders and have agreed not to redeem themselves.
Petra initially announced its $128 million combination with Revelation on August 30. San Diego-based Revelation is developing two drug candidates aimed at treating respiratory diseases as well as a diagnostic device for diagnosing viral infections.
On December 1, it initiated Phase 2b trials for REVTx-99 to test its efficacy in treating the flu while this drug began Phase 1b trials for treating allergic rhinitis and chronic nasal congestion the month before.
ADVISORS
- Roth Capital Partners is acting as financial advisor to Revelation
- LifeSci Capital is acting as financial and capital markets advisor to Petra
- Loeb & Loeb LLP is acting as legal counsel to Petra
- Fox Rothschild LLP and J.P. Galda & Co are acting as legal counsel to Revelation
Globa Terra Acquisition Corporation (NASDAQ:GTERU) has filed for a $152.2 million SPAC to find an agriculture or food-tech target company The new SPAC is overfunded to 100.5% and is set to have both a 3/4 warrant and right to a 1/20 share in each of its units. This vies for the most investor-friendly unit coverage of...
EGH Acquisition Corp. (NASDAQ:EGHAU) has filed for a $150 million SPAC to continue the work of the Tortoise serial SPAC team under a fresh name. The new SPAC is not overfunded and will have one right to a 1/10 share in each of its units. It will have 24 months to initially close a business...
Yorkville Acquisition Corp. has filed for a $150 million SPAC to bring the sponsor’s experience in SPAC investing to a search for a technology, media or telecom target. The new SPAC is overfunded to 100.5% with $10.05 per unit in trust initially. Each unit is set to contain a 1/3 share and it will have...
At the SPAC of Dawn This week’s trading comes to an end later today as the US exchanges will observe the Good Friday holiday (but the SEC’s EDGAR filing system will not). Dow futures ahead of this session remain in the red although both the S&P 500 and Nasdaq look to make up some losses...
This week, we return to another episode from 2021, when we spoke with Will Marshall, Co-founder and CEO of Planet Labs (NYSE:PL). Planet provides data services drawn from its fleet of about 200 satellites that generate a complete image of the earth’s surface every day. It just celebrated its first quarter of EBITDA profitability, but at...